Project Grant R01CA282098

Award Date 7/18/24
Completion Date 6/30/29
Dollars Obligated $949K
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
This $3.3 million project grant from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) supports research to identify prediagnostic exposures, germline genetics, and immune and mutational profiles associated with triple negative breast cancer (TNBC). Joan & Sanford I Weill Medical College of Cornell University is the primary awardee and will perform whole exome sequencing of tumor and germline DNA from 400 TNBC patients across four prospective cohort...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $215,311 to the University of Texas Health Science Center at Houston to develop and evaluate antibody-drug conjugates (ADCs) that target the GPR56 receptor for the treatment of triple-negative breast cancer (TNBC). The key objectives are to: 1) Generate GPR56-targeted ADCs by attaching various cytotoxic drugs and assess their cell-killing potency in TNBC cell lines; 2) Evaluate the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $631,492 to The University of Kentucky Research Foundation to conduct research aimed at identifying nicotinamide N-methyltransferase (NNMT) as a new target for treating triple-negative breast cancer (TNBC). The key goals are to define how NNMT promotes anchorage-independent growth and protects TNBC cells from ferroptosis, evaluate the efficacy of a newly developed NNMT bisubstrate...
This $398,728 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of a novel homologous recombination (HR) inhibitor, CP-8, to sensitize triple-negative breast cancer (TNBC) cells to DNA-damaging agents. The project aims to examine the synergy of CP-8 with various DNA-damaging therapies, including PARP inhibitors and ionizing radiation, in TNBC cell lines, patient-derived xenograft models, and in vivo...
This Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Dartmouth-Hitchcock Clinic provides $442,343.00 in funding starting on March 19, 2025 to support research on therapeutic targeting of the tumor microenvironment in triple negative breast cancer patients at high risk of relapse. The key objectives are to test the hypothesis that copper depletion using tetrathiomolybdate (TM) can prevent cancer relapse by disrupting three key aspects of...
This federal Project Grant award of $399,129 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Johns Hopkins University aims to develop a novel treatment strategy for triple-negative breast cancer (TNBC). The research will investigate combining a DDX3 inhibitor (RK-33) to alter the tumor's metabolic environment with immunotherapy to generate an effective and sustained immune response against TNBC. Specifically, the grant will fund research under three key...
The National Cancer Institute (NCI) awarded Virginia Commonwealth University (VCU) a $1,241,427 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate a small molecule inhibitor called PDZ1I for treating advanced, metastatic triple negative breast cancer (TNBC). The project aims to formulate PDZ1I-nano for clinical use, characterize how it stimulates the immune system to suppress tumor growth, define the signaling pathways it targets, and combine it...
This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research), supports research to evaluate the preclinical and clinical activity of DNA methyltransferase (DNMT) inhibitors in combination with chemoimmunotherapy for patients with triple-negative breast cancer (TNBC). The $472,447 award, effective December 1, 2024, focuses on identifying biomarkers, such as DNMT3A expression, that can predict response to these targeted therapies. The proposed...
This federal Project Grant award of $781,436 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by Cold Spring Harbor Laboratory (CSHL) to optimize anti-N-methyl-D-aspartate receptor (NMDAR) antibodies for the treatment of triple-negative breast cancer (TNBC). The key goals are to: 1) establish an orthotopic mouse model with inducible NMDAR expression in TNBC tumors, 2) screen for NMDAR-reactive antibodies and use cryo-electron microscopy to identify...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $619,764 to the University of Wisconsin - Madison to develop new combination immunotherapy strategies for treating triple-negative breast cancer (TNBC). The key objectives are to: 1) increase the tumor-selective accumulation of a platelet-mediated immune checkpoint inhibitor (P-aPDL1) by triggering local thrombus formation in TNBC tumors, and 2) modulate the immunosuppressive...

TARGETING METABOLIC VULNERABILITIES OF TRIPLE NEGATIVE BREAST CANCER STEM CELLS - PROJECT SUMMARY/ABSTRACT TRIPLE NEGATIVE BREAST CANCER (TNBC) IS THE MOST AGGRESSIVE SUBTYPE WITH INCREASED PROPENSITY FOR METASTASIS AND FEW TREATMENT OPTIONS. MOUNTING EVIDENCE SUGGESTS THAT CANCER STEM-LIKE CELLS (CSCS) IN TNBC CONTRIBUTE TO THE EARLY RECURRENCE AND POOR CLINICAL OUTCOMES. THUS, IDENTIFICATION OF NOVEL THERAPEUTIC APPROACHES EFFECTIVELY TARGETING CSCS IS CRUCIAL FOR IMPROVING OUTCOME IN TNBC. WE PROPOSE TO TARGET CSCS IN TNBC BY EXPLOITING THEIR OVEREXPRESSION OF TWO REDOX REGULATING ENZYMES, NQO1 AND SOD1 AS A THERAPEUTIC VULNERABILITY. UTILIZING A POTENT NQO1-BIOACTIVATABLE REDOX CYCLING COMPOUND, IB-DNQ, WHICH GENERATES LARGE AMOUNTS OF REACTIVE OXYGEN SPECIES IN CSCS VIA FUTILE REDOX CYCLING, WE PROPOSE TO EXAMINE THE FEASIBILITY OF UTILIZING IB- DNQ ALONE, OR IN COMBINATION WITH SOD1 INHIBITION, TO EFFECTIVELY TARGET CSCS ACROSS THE EMT-MET CSC STATE CONTINUUM. WE WILL ADDRESS THREE SPECIFIC AIMS: 1) TO DEMONSTRATE THE EFFICACY OF IB-DNQ ALONE OR IN COMBINATION WITH SOD1 INHIBITION IN TARGETING CSCS IN VITRO AND IN MOUSE MODELS OF HUMAN TNBC; 2) TO DETERMINE THE MECHANISMS OF CELL DEATH INDUCED BY IB-DNQ BASED PRO-OXIDANT STRATEGIES; AND 3) TO DETERMINE HOW IB-DNQ BASED PRO-OXIDANT STRATEGIES MODULATE ANTITUMOR IMMUNITY IN IMMUNOCOMPETENT MOUSE MODELS. THIS PROPOSAL WILL EVALUATE A NOVEL PRO-OXIDANT-BASED APPROACH IN SELECTIVELY TARGETING CSCS IN TNBC AND ELUCIDATE THE MECHANISM OF ACTION FOR FUTILE OXIDANT GENERATORS IN ACTIVATING MITOCHONDRIAL APOPTOTIC AND PYROPTOTIC CELL DEATH WITH RESULTANT STIMULATION OF ANTITUMOR IMMUNITY. AS NQO1 AND SOD1 ARE OVEREXPRESSED IN MANY SOLID TUMORS, THIS THERAPEUTIC STRATEGY MAY HAVE WIDE APPLICABILITY.

Posted 7/18/24, 12:00 AM